John Crowley became the CEO of Amicus Therapeutics Inc (NASDAQ:FOLD) in 2011. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap shot of the business growth. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This method should give us information to assess how appropriately the company pays the CEO.
How Does John Crowley’s Compensation Compare With Similar Sized Companies?
According to our data, Amicus Therapeutics Inc has a market capitalization of US$2.4b, and pays its CEO total annual compensation worth US$6m. Notably, that’s an increase of 34% over the year before. We looked at a group of companies with market capitalizations from US$2.0b to US$6.4b, and the median CEO compensation was US$5m.
So John Crowley is paid around the average of the companies we looked at. This doesn’t tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.
Is Amicus Therapeutics Inc Growing?
Over the last three years Amicus Therapeutics Inc has shrunk its earnings per share by an average of 18% per year. Its revenue is up 291% over last year.
As investors, we do are a bit wary of companies that have lower earnings per share, over three years. But in contrast the revenue growth is strong, suggesting future potential for earnings growth. It’s hard to reach a conclusion about business performance right now. This may be one to watch.
You might want to check this free visual report on analyst forecasts for future earnings.
Has Amicus Therapeutics Inc Been A Good Investment?
Most shareholders would probably be pleased with Amicus Therapeutics Inc for providing a total return of 57% over three years. So they may not be at all concerned if the CEO is paid more than is normal for companies around the same size.
Remuneration for John Crowley is close enough to the median pay for a CEO of a similar sized company .
The company isn’t showing particularly great growth, but shareholder returns have been pleasing. So all things considered I’d venture that the CEO pay is appropriate. Shareholders may want to check for free if Amicus Therapeutics Inc insiders are buying or selling shares.
Or you might prefer this data-rich interactive visualization of historic revenue and earnings.
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at email@example.com.